AI Article Synopsis
- - Glioblastoma is the most common and aggressive brain tumor in adults, typically treated through surgery combined with radiation and chemotherapy, but it has a poor survival rate with an average of only 15 months.
- - Despite improvements in understanding the disease, glioblastoma is still on the rise, affecting patients' quality of life and showing a high rate of recurrence.
- - Recent literature analysis highlights the current treatment standards and patient outcomes, while also showcasing new therapies like cancer vaccines and personalized medicine that may offer hope for better management of glioblastoma in the future.
Article Abstract
Glioblastoma is the most common malignant brain tumor in adults. The current management relies on surgical resection and adjuvant radiotherapy and chemotherapy. Despite advances in our understanding of glioblastoma onset, we are still faced with an increased incidence, an altered quality of life and a poor prognosis, its relapse and a median overall survival of 15 months. For the past few years, the understanding of glioblastoma physiopathology has experienced an exponential acceleration and yielded significant insights and new treatments perspectives. In this review, through an original R-based literature analysis, we summarize the clinical presentation, current standards of care and outcomes in patients diagnosed with glioblastoma. We also present the recent advances and perspectives regarding pathophysiological bases as well as new therapeutic approaches such as cancer vaccination and personalized treatments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065751 | PMC |
| http://dx.doi.org/10.3390/jpm11040258 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!